AcelRx Pharma (ACRX) Posts Suprise Q3 Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Jefferies Asumes, Upgrades AcelRx Pharmaceuticals (ACRX) to Buy
October 30, 2015 7:22 AM EDTJefferies assumes, upgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Hold to Buy with a price target of $7.00 (from $3.50).
Analyst Hugo Ong commented, "We are upgrading ACRX to a Buy (v. Hold previously) with a $7 PT (v. $3.50 previously), shifting our focus to ARX-04. While... More
